The test is intended to help identify patients eligible for treatment with Sarepta Therapeutics’ ELEVIDYS gene therapy for individuals with Duchenne muscular dystrophy, according to an Aug. 30 news release.
Quest also announced its collaboration with Sarepta to develop other diagnostics to complement Sarepta’s gene therapies. It will also provide clinical lab testing for Sarepta.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
